Europe needs to learn from US shareholders willing to make big bets on biotech if it wants to create a thriving homegrown industry, according to the chief executive of Argenx, one of the bloc’s largest biotech companies.
Tim Van Hauwermeiren told the Financial Times that Europe has a “chicken and egg” problem: specialist healthcare funds are scarce because not enough biotechs are available to invest in — and biotechs are scarce because domestic investors do not support them.
您已閱讀16%（642字），剩餘84%（3280字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。